A phase I dose escalation and dose expansion study of the anti-programmed cell death-1 (PD-1) antibody AK105.

Citation

• Kotasek, D., Coward, J., de Souza, P. L., Underhill, C., Jin, X., Li, B., . . . Prawira, A. (2019). A phase I dose escalation and dose expansion study of the anti-programmed cell death-1 (PD-1) antibody AK105.. Journal of Clinical Oncology, 37(15_suppl), e14006. doi:10.1200/jco.2019.37.15_suppl.e14006

Digital Object Identifier (doi)

• 10.1200/jco.2019.37.15_suppl.e14006

Web Of Science Accession Number

Start Page

• e14006

End Page

• e14006

Volume

• 37

Issue

• 15_suppl

Place Of Publication

Abstract

UOW Authors

•   De Souza, Paul (external author)

Publication Date

• 2019

Publisher

• American Society of Clinical Oncology (ASCO) 

Published In

• Journal of Clinical Oncology  Journal

Citation

• Kotasek, D., Coward, J., de Souza, P. L., Underhill, C., Jin, X., Li, B., . . . Prawira, A. (2019). A phase I dose escalation and dose expansion study of the anti-programmed cell death-1 (PD-1) antibody AK105.. Journal of Clinical Oncology, 37(15_suppl), e14006. doi:10.1200/jco.2019.37.15_suppl.e14006

Digital Object Identifier (doi)

• 10.1200/jco.2019.37.15_suppl.e14006

Web Of Science Accession Number

Start Page

• e14006

End Page

• e14006

Volume

• 37

Issue

• 15_suppl

Place Of Publication